Smith+Nephew to feature new Sports Medicine technology for joint repair and connected arthroscopic tower during AAOS 2021 Annual Meeting

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2021 Annual Meeting being held in San Diego, CA.

The latest technologies include:

FAST-FIX^◊ FLEX Meniscal Repair System: The only device to offer a surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus. ^1-3 Improving access leads to a greater opportunity to repair the meniscus rather than remove it, resulting in long-term benefits to the patient.^4-6 link to press release

INTELLIO^◊ Connected Tower: Uses a centralized app to wirelessly connect and control the major components of an arthroscopy surgical tower from outside the sterile field, helping to streamline procedure support. Recent advancements to the connected tower include a new pump and 4K optimized scopes. link to press release 

• DOUBLEFLO^◊ Inflow/Outflow Pump: Designed to be simple, effective and connected, the DOUBLEFLO Pump is able to respond to a surgeon’s needs in diverse clinical situations.^7,8 It can be controlled remotely by the LENS^◊ Connected Tower App and offers heads-up display projection on the arthroscopic tower, allowing surgeons to focus on the patient rather than equipment.

• 4KO^◊ (Optimized) Arthroscopes and Laparoscopes: Expands 4K surgical imaging portfolio for multi-specialty centers. Designed with improved image quality, the 4KO Direct View (DV) Arthroscopes have a 30% minimum increase in resolution compared to Smith+Nephew HD DV arthroscopes⁹. And by offering C-mount and Direct View coupling, surgeons have the flexibility to choose the scope that works best for them based on procedure type and surgical preference.
  
  

WEREWOLF^◊ FASTSEAL 6.0 Hemostasis Wand: Using low temperature thermal energy¹⁰, the WEREWOLF FASTSEAL 6.0 Hemostasis Wand delivers hemostatic sealing (via coagulation) during open orthopaedic procedures such as total joint arthroplasty (TJA) – such technology has shown to significantly reduce total blood loss^*11 as well as significantly shortening procedure time.^**12 link to press release 

REGENETEN^◊ Bioinductive Implant: Supports the body’s natural healing response by inducing the growth of new tendon-like tissue^13-16 to biologically augment the existing tendon and disrupt disease progression.^13-17 Delivered arthroscopically through a small incision over the location of the rotator cuff tendon injury, the implant is about the size of a postage stamp and is completely resorbed within six months.^***15,18  A new study shows how REGENETEN is setting a new standard of recovery for partial-thickness rotator cuff tears. link to press release 

CAP-FIX^◊ Suture Passer: A direct style passer designed specifically for the passage and retrieval of suture through the hip capsule to facilitate capsular closure. The tip and hook geometry have been optimized for strength, sharpness, trajectory, and suture throw and are available in 45 and 70 degree angles.^19-20 It is compatible with Vicryl™ Size #2 (a specific absorbable suture) as well as other Smith+Nephew standard suture offerings.²⁰  

SPORTPORT^® Cannula: A soft, flexible cannula designed to accommodate a surgeon’s access and range-of-motion in the joint space with easy insertion and a cannulated disposable obturator. The cannula’s flexibility streamlines the surgeon’s procedure by facilitating access to anatomy. Available in two sizes, it is designed to adjust to a surgeon’s diverse clinical needs.

To learn more about these ground-breaking Sports Medicine innovations, please stop by the Smith+Nephew booth (#1735) during AAOS 2021.

Enquiries

*compared to monopolar electrocautery for THA using an anterolateral approach (p=0.0001, n=50)

**compared to monopolar electrocautery for infected revision total knee arthroplasty (TKA)(p=0.044, n=80)

***On human biopsy (n=1) and in-vivo sampling

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees  deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.